Graeme Brookes has led and served as a board member of multiple medical device businesses. Previously, he was CEO at Reapplix A/S (Denmark) taking a device-based cell and growth factor therapy through development, regulatory clearances, clinical trial completion (published in The Lancet) and high-level US reimbursement. Prior to this he was VP Global R&D and marketing at Stanmore Implants (orthopaedics), CEO at Acrobot (orthopaedic robotics), Sales & Marketing Director at Advanced Medical Solutions plc (wound care) and held Business Development and Sales & Marketing leadership roles at Johnson & Johnson (Orthopaedics / Neurosurgery). Additionally, he worked in manufacturing, R&D and marketing at Amersham International (radiopharmaceuticals).

Peter Hentschel has more than 40 years’ experience of the Medical Device Industry and has led several businesses both operationally as well as  serving as a Board member. Previously he was Senior Vice President of Mölnlycke Health Care, CEO of Etac AB and had senior positions within SCA Hygiene Products. He has served as a Board member at a large number of companies, and has been Chairman of the Board at RLS Global AB, Reapplix A/S, Diasend AB and Lumina Adhesives AB.

Markus Fagerlund acts as partnership and commercial advisor. He has more than 25 years of experience from sales & marketing positions in companies like Xerox, Datscha and Newsec and many years as a leader. He is entrepreneurial with long experience in building up new business areas. Fagerlund has an international education in Marketing & Communication.

Maria has over 15 years of experience in marketing, strategy, business development, investment, and investor relations within the Life Science and MedTech industry, in senior roles. Maria holds a Master of Science in Molecular Biology from Uppsala University and a degree in Marketing and Business Administration from the School of Entrepreneurship, Uppsala University.

40 years’ experience of leading large life science companies, as well as start-ups. Most recently Tomas held a position as CEO in Sweden of Siemens Healthcare AB. Tomas has also been a board member and chairman of the board in large and small companies.    

Linda has 20 years combined experience from the pharmaceutical industry (Biovitrum, AstraZeneca) academia (Dept. of Microbiology, New York University), clinical microbiology (Karolinska University Hospital) and the medical device industry (Bactiguard). Main competence areas include microbiology, molecular biology, biocompatibility, clinical studies, quality management systems, licensing, regulatory affairs and characterization of mechanism of action of coatings. Experience in managing labs, project management, scientific communication and collaborations.

Åsa is an organic chemist with experiences in organic synthesis, NMR analysis and Wood chemistry. She holds a B.Sc. and a M.Sc in organic chemistry from Stockholm University.

Elena has a BSc in Food Science and Technology from University of West Athens, Greece, and several years of experience from Microbiological Quality Control testing using several standardised techniques, and both microbiological, biochemical and molecular biology test methods.

Serhiy has over 15 years of experience in a vast array of microbiology, biochemistry and molecular biology methods, specializing in molecular genetics of microorganisms, and proteomics. In his doctorate he showed the way tmRNA is positioned during late steps of trans-translation in E. coli, using cryo-EM tomography and RNA probing techniques. Serhiy is in charge of the antimicrobial testing and validation of the CytaCoat technology, he is also developing new methods and specific culture mediums.

Dr. Ana Romero has expertise in academic and industry product development. She was one of the principal investigators in the discovery and development of the EMA-approved drug Ceplene. Ana has also been involved in the data management and evaluation of worldwide clinical trials and big data studies. She holds a PharmD and a PhD from Gothenburg University with postdoctoral research work at the Cancer Institute Gustave Roussy, Paris. 

Dr Alan Rhodes has over 16 years’ experience developing and commercialising surface modification and coating technologies, within the medical device industry. He is Director and Principal Consultant at DSR Biomaterials, providing strategic and technical support in surface modification and coating strategies. Alan is a Chartered Chemist (CChem), Chartered Scientist (CSci) and co-inventor on five patents.